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Other Specific Nephropathies S63markedly upregulated in mouse kidney with unilateral ureteral obstruction
(UUO). In this study, we characterized and investigated the regulatory mecha-
nisms and functional role of lncRNA_5318 in renal fibrosis in vitro and in vivo.
Methods: In vitro, the regulatory mechanism of lncRNA_5318 was determined
in TGF-b1-stimuatedmouse tubular epithelial cells (mTECs) with addition of a
Smad3 inhibitor (SIS3). The functional role of lncRNA_5318 in renal fibrosis was
examined in mTECs with knockdown of lncRNA_5318. Furthermore, the func-
tional role and therapeutic potential of lncRNA_5318 for renal fibrosis was
investigated in a mouse UUO model by ultrasound mediated shRNA transfer.
Results: We found that upregulation of lncRNA_5318 in UUO kidney was asso-
ciated with marked activation of TGF-b/Smad3 signaling and progressive
renal fibrosis. In vitro study showed that addition of TGF-b1 induced signif-
icant upregulation of lncRNA_5318 in mTECs by time and dose dependent
manners, which was suppressed by blocking Smad3 signaling with SIS3,
demonstrating a TGF-b/Smad3-dependent regulatory mechanism of
lncRNA_5318 during renal fibrosis. Knockdown of lncRNA_5318 on mTECs
inhibited TGF-b1- induced expression of collagen I and a-SMA which revealed
the functional role of lncRNA_5318 in TGF-b-induced fibrosis. Furthermore,
we also demonstrated that gene therapy of mouse UUO by shRNA was
capable of blocking lncRNA_5318, thereby inhibiting renal fibrosis.
Conclusion: lncRNA_5318 is positively regulated by TGF-b/Smad3 signaling
and functions to medicate renal fibrosis. Inhibition of progressive renal
fibrosis by blocking lncRNA_5318 with shRNA demonstrates a novel therapy
for renal fibrosis by targeting lncRNA_5318.http://dx.doi.org/10.1016/j.hkjn.2015.09.0130081
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Background: Autosomal dominant polycystic kidney disease (ADPKD) is the
most common monogenic kidney disease. Genetic testing of ADPKD is expen-
sive because of 6 pseudogenes and 33 exons in PKD1. Previous methods
included (1) long range PCR followed by direct sequencing, (2) whole-exome
sequencing with custom-made target capture array, and (3) long-range PCR
amplicons and barcoded libraries followed by next generation sequencing.
We propose a cost effective method by target sequencing of combining
multiplex PCR amplicons followed by next generation sequencing.
Methods: We studied 51 PKD patients diagnosed as ADPKD with typical
numerous renal cysts with or without family history.We compared ourmethod
with traditional method and validated by a traditional method in 20 cases.
Results: Themutation detection rate is 80% in the cohort. PKD2mutations per-
centage are higher in the Taiwan ADPKD population (35.3%) compared to pre-
vious report (15%). Several novelmutations are found in PKD1 and PKD2. There
was no hot spot in PKD1. A hot spot R803X of PKD2 was found in 15% of the
cohort, and a funder effect was suspected. The renal survival was better in
those with PKD2 mutation. The renal survival in PKD2 patients with mutation
after the intracellular coil-coil domain was not better than those with muta-
tion before this area. The cost of this method is below US$300 per person.
Conclusion: Our method generates a reasonable detection rate with lower
price. Individual treatment based on genetic diagnosis could a future of
ADPKD treatment.http://dx.doi.org/10.1016/j.hkjn.2015.09.0140082
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Objectives: To assess the prevalence of anti-phospholipase A2 receptor
(anti-PLA2R) antibody in a cohort of patients with idiopathic membranousnephropathy (MN) in Taiwan and to correlate the presence of anti-PLA2R
antibody with the clinical parameters reflective of disease activity. In
addition, to monitor disease activity using levels of anti-PLA2R antibody
in MN.
Methods: The preliminary report was a cross-sectional in prevalent patients
with MN, which prospective collection of serum and urine checked together
with clinical data. MN definitively pathological diagnosis, not only new inci-
dent (treatment naı¨ve) patients, but also active patients entering therapeu-
tic trial (including immunosuppressive agents) and adult patients > 18 years
old are enrolled. We quantified anti-PLA2R antibody by ELISA (EUROIMMUN
AG) that provides reliable determination and also quantification of autoan-
tibodies (IgG) against PLA2R.
Results: So far, the number of MN cases collected is 17. Control group,
including other glomerculonephritis or health people is 13. In four of those
17 MN patients, anti-PLA2R antibodies were positive (detectable > 20 RU/
ml, ELISA). None of control group was positive anti-PLA2R antibodies. The
prevalence of anti-PLA2R antibodies was relatively low compared to China
cohort, because our cohort was cross-sectional study. Serum samples
collected from MN patients were almost those accepted steroid or other
immunosuppressant agents. Anti-PLA2R antibodies might be underesti-
mated. Changes in serum anti-PLA2R antibodies levels as dynamic clinical
parameters for disease activity are enrolling. So far, it showed no this asso-
ciation. However, we observe anti-PLA2R antibody levels may correlate with
urinary excretion of b2 microglobulin or IgG, a marker of renal damage
rather than proteinuria.
Conclusion: The preliminary report did not demonstrate the association be-
tween the disease activities with anti-PLA2R antibodies in idiopathic MN
from the experience in Southern Taiwan.http://dx.doi.org/10.1016/j.hkjn.2015.09.0150108
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Background: Serum soluble urokinase-type plasminogen activator receptor
(suPAR) is implicated in the pathogenesis of native and recurrent FSGS. It
is elevated in two-thirds of subjects with primary FSGS, but not in people
with other glomerular diseases which can differentiate FSGS and other
glomerular diseases.
Methods: We measured soluble urokinase receptor levels in the resum
of patients with primary focal segmental glomerulosclerosis (FSGS)
and determined their association with clinical and pathological data in
86 patients with primary FSGS, 5 repeat renal biopsy FSGS and 6
recurrent FSGS posttranplantation, healthy controls and patients
with minimal change disease, and membranous nephropathy were
used as controls. The suPAR levels were measured by commercial ELISA
kits.
Results: Of patients with primary FSGS (median 4232, interquartile range
1299e9714 pg/ml) were significantly higher than those of patients with min-
imal change disease (median 2784 pg/ml), membranous nephropathy (me-
dian 3478 pg/ml), and healthy individuals (median 1994 pg/ml). There was
no significant difference in suPAR levels between the 65 patients with min-
imal change disease and 85 patients with membranous nephropathy. The
suPAR levels increased in the 5 repeated renal biopsy FSGS and 6 recurrent
FSGS posttranplantation.
Conclusion: The suPAR levels were significantly but positively correlated
with FSGS, not only primary FSGS but also recurrent FSGS posttransplanta-
tion, but negatively correlated with other glomerular diseases. Thus,
suPAR levels can differentiate primary FSGS and other glomerular
diseases.http://dx.doi.org/10.1016/j.hkjn.2015.09.016
